

CQ 15-6

敗血症性 DIC にタンパク分解酵素阻害薬の投与を行うか？

検索データベース

- MEDLINE (PubMed/Ovid)
- CENTRAL
- 医学中央雑誌
- その他 ()

検索式とヒット数

PubMed search strategy (検索日 2019 年 5 月 7 日)

#1	sepsis[MeSH Terms] OR "multiple organ failure"[MeSH Terms] OR "shock, septic"[MeSH Terms] OR infection[MeSH Terms]	776749
#2	"disseminated intravascular coagulation"[MeSH Terms]	10791
#3	"protease inhibitors"[MeSH Terms] OR gabexate[MeSH Terms] OR nafamostat[Title/Abstract] OR nafamstat[Title/Abstract]	112473
#4	randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR "drug therapy"[Subheading] OR randomly[tiab] OR trial[tiab] OR groups[tiab] NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms])	3893704
#5	(#1 OR #2) AND #3 AND #4	1333
#6	#5 AND 15361940 [uid]	1

CENTRAL search strategy (検索日 2019 年 5 月 2 日)


#1	MeSH descriptor: [Sepsis] explode all trees	4028
#2	MeSH descriptor: [Multiple Organ Failure] explode all trees	387
#3	MeSH descriptor: [Shock, Septic] explode all trees	784
#4	MeSH descriptor: [Infection] explode all trees	22648
#5	#1 OR #2 OR #3 OR #4	23524
#6	MeSH descriptor: [Disseminated Intravascular Coagulation] explode all trees	106
#7	#6	106
#8	MeSH descriptor: [Protease Inhibitors] explode all trees	6733
#9	MeSH descriptor: [Gabexate] explode all trees	45
#10	(nafamostat):ti,ab,kw	74

#11	(nafamstat):ti,ab,kw	23
#12	#8 OR #9 OR #10 OR #11	6807
#13	(#5 OR #7) AND #12	133

医学中央雑誌 search strategy(検索日 2019年5月2日)

#1	((敗血症/TH or 敗血症/TA or sepsis/TA or septic/TA) and (PT=会議録除く)) and (PT=会議録除く)	23378
#2	(ショック-敗血症性/TH or 敗血症性ショック/TA) and (PT=会議録除く)	6161
#3	(全身性炎症反応症候群/TH or 全身性炎症反応症候群/TA or systemic/AL and inflammatory/AL and response/AL and syndrome/TA or SIRS/TA) and (PT=会議録除く)	1609
#4	(多臓器不全/TH or 多臓器不全/TA) and (PT=会議録除く)	6294
#5	(DIC/TH or DIC/TA or "Disseminated Intravascular Coagulation"/TA or 播種性血管内凝固/TA) and (PT=会議録除く)	43896
#6	(血液凝固異常/TH or 血液凝固異常/TA and or 過凝固/TA or 凝固障害/TA or 凝固亢進/TA) and (PT=会議録除く)	1521
#7	#1 OR #2 OR #3 OR #4 OR #5 OR #6	70427
#8	("Protease Inhibitors"/TH or 蛋白分解酵素阻害薬/AL or Gabexate/TH or Gabexate/TA or Nafamostat/TH or Nafamostat/TA) and (PT=会議録除く)	39171
#9	ランダム化比較試験/TH or 準ランダム化比較試験/TH or ランダム化/AL or 無作為化/AL or 比較試験/AL or 臨床試験/AL or プラセボ/AL or 対照/AL or コントロール/AL or 臨床研究/AL	302233
#10	#7 AND #8 AND #9	307


PRISMA フロー図




	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Hsu 2004	●			●	●		●
Nishiyama 2000				●	●		●

フォレストプロット

アウトカム① Mortality at 1 month




アウトカム② GI bleeding



ファンネルプロット

アウトカム① Mortality at 1 month



アウトカム② GI bleeding

